L575-0317 Screening compound: 1-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-(pyrrolidin-1-yl)butane-1,4-dione

L575-0317 Screening compound: 1-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-(pyrrolidin-1-yl)butane-1,4-dione
L575-0317 Screening compound: 1-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-(pyrrolidin-1-yl)butane-1,4-dione alternative view

Chemical Structure Depiction of ChemDiv screening compound L575-0317
1-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-(pyrrolidin-1-yl)butane-1,4-dione

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L575-0317

Molecular Formula

C21H31N5O3 (C21 H31 N5 O3)

Compound Name

1-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-(pyrrolidin-1-yl)butane-1,4-dione

IUPAC name

1-[1-methyl-3-(piperidine-1-carbonyl)-1H4H5H6H7H-pyrazolo[43-c]pyridin-5-yl]-4-(pyrrolidin-1-yl)butane-14-dione

SMILES

Cn1nc(C(N2CCCCC2)=O)c(C2)c1CCN2C(CCC(N1CCCC1)=O)=O

InChI

InChI=1S/C21H31N5O3/c1-23-17-9-14-26(19(28)8-7-18(27)24-10-5-6-11-24)15-16(17)20(22-23)21(29)25-12-3-2-4-13-25/h2-15H2,1H3

InChI Key

DHRNIQHKLDYCEF-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27463524

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

401.51

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

0.00

Rotatable Bond Count

7.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

0.037

Distribution Coefficient, logD

0.037

Water Solubility, LogSw

0.36

Polar Surface Area

64.446

Acid Dissociation Constant (pKa)

22.09

Base Dissociation Constant (pKb)

2.93

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

71.40

L575-0317 in Drug Discovery

Included in Screening Libraries

Anticancer Library (62698 compounds)

Cysteine Proteases Inhibitors Library (7839 compounds)

GPCR Targeted Library (31838 compounds)

Hsp90-Targeted Library (11355 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
Targets:
  • Proteases
  • GPCR
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with L575-0317 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L575-0317?
Check Price and Availability of L575-0317, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L575-0317 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L575-0317
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L575-0317
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L575-0317 available by request